Literature DB >> 2292708

Efficacy of sublingual apomorphine in Parkinson's disease.

F Durif, D Deffond, M Tournilhac.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2292708      PMCID： PMC488328          DOI： 10.1136/jnnp.53.12.1105

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  Similarities between neurologic effects of L-dopa and of apomorphine.

Authors:  G C Cotzias; P S Papavasiliou; C Fehling; B Kaufman; I Mena
Journal:  N Engl J Med       Date:  1970-01-01       Impact factor: 91.245

2.  Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors:  C M Stibe; A J Lees; P A Kempster; G M Stern
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

3.  Subcutaneous apomorphine in Parkinson's disease.

Authors:  W Poewe; B Kleedorfer; F Gerstenbrand; W Oertel
Journal:  Lancet       Date:  1988-04-23       Impact factor: 79.321

4.  Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa.

Authors:  F Lhermitte; Y Agid; J L Signoret
Journal:  Arch Neurol       Date:  1978-05

5.  [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].

Authors:  P Pollak; A S Champay; J M Gaio; M Hommel; A L Benabid; J Perret
Journal:  Rev Neurol (Paris)       Date:  1990       Impact factor: 2.607
  5 in total
  3 in total

1.  Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease.

Authors:  F Durif; E Jeanneau; F Serre-Debeauvais; D Deffond; A Eschalier; M Tournilhac
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.

Authors:  L Ostergaard; L Werdelin; P Odin; O Lindvall; E Dupont; P B Christensen; E Boisen; N B Jensen; S H Ingwersen; M Schmiegelow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-06       Impact factor: 10.154

3.  Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

Authors:  K Pietz; P Hagell; P Odin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.